{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T18:40:20Z","timestamp":1756233620072,"version":"3.44.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Malignant peritoneal mesothelioma (MPM) is a rare disease that progresses within the peritoneal cavity and only disseminates to systemic sites in the terminal months of the disease. For this malignancy, there are several regimens of chemotherapy that have been accepted as standard, principally intraperitoneal chemotherapy (IPC) and intravenous chemotherapy (IVC); however, there is no standardized method of treatment. Selected patients with MPM who are amenable to cytoreductive surgery (CRS) and are fit for surgery typically undergo resection with hyperthermic intraperitoneal chemotherapy (HIPEC). Though individual toxicity and efficacy studies of IPC plus IVC (bidirectional) and IVC chemotherapy for MPM have been conducted, a prospective randomized clinical trial has not been performed for this disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods:<\/jats:title>\n            <jats:p>The study objective is to compare the efficacy and toxicity of normothermic bidirectional (IPC\/IVC) chemotherapy versus IVC after CRS and HIPEC for epithelial MPM. The patient population are those individuals undergoing CRS for MPM. Exclusion criteria include previous therapy form mesothelioma. The study design is a randomized, nonblinded, phase II clinical trial comparing multicycle IVC with cisplatin (CDDP) and pemetrexed (PMTX) versus multicycle bidirectional chemotherapy with IVC CDDP and IPC PMTX after optimal CRS and HIPEC with CDDP and doxorubicin. The primary endpoint is 2-year disease-free survival. The secondary endpoint is 30-day post-treatment morbidity. The primary objective is to compare the 2-year rates of disease-free survival in the two treatment arms. The secondary objective is to compare the toxicity of each treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Dissemination:<\/jats:title>\n            <jats:p>The prospective randomized trial provides not only a standardized approach to treatment but also a path forward to optimize the survival of patients with MPM. In addition, any increase or decrease in the adverse events associated with PMTX administered as IPC will be demonstrated. Because MPM is a rare disease a multi-institutional implementation of the protocol is required.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/sp9.0000000000000010","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T04:03:36Z","timestamp":1695873816000},"page":"108-117","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Randomized trial of intravenous versus bidirectional chemotherapy after cytoreductive surgery for malignant peritoneal mesothelioma"],"prefix":"10.1097","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2431-7366","authenticated-orcid":false,"given":"Paul H.","family":"Sugarbaker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,12]]},"reference":[{"issue":"Suppl. 4S","key":"R1-20250826","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/jco.2016.34.4_suppl.295","article-title":"Long term outcome in patients with advanced malignant peritoneal mesothelioma (AbM) treated with a pemetrexed\/platin combination","volume":"34","author":"Karthaus","year":"2016","journal-title":"J Clin Oncol"},{"key":"R2-20250826","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1245\/s10434-012-2845-x","article-title":"The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy","volume":"20","author":"Deraco","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"R3-20250826","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.06.002","article-title":"Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study","volume":"65","author":"Kepenekian","year":"2016","journal-title":"Eur J Cancer"},{"key":"R5-20250826","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/annonc\/mdp307","article-title":"Malignant peritoneal mesothelioma: a multicenter study on 81 cases","volume":"21","author":"Manzini","year":"2010","journal-title":"Ann Oncol"},{"key":"R6-20250826","doi-asserted-by":"crossref","first-page":"6237","DOI":"10.1200\/JCO.2009.23.9640","article-title":"Cytoreductive surgery and hyperthermic intra peritoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience","volume":"27","author":"Yan","year":"2009","journal-title":"J Clin Oncol"},{"key":"R7-20250826","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1097-0142(196709)20:9<1351::AID-CNCR2820200902>3.0.CO;2-#","article-title":"Selective heat sensitivity of cancer cells. Biochemical and clinical studies","volume":"20","author":"Cavaliere","year":"1967","journal-title":"Cancer"},{"key":"R8-20250826","doi-asserted-by":"crossref","first-page":"68","DOI":"10.4251\/wjgo.v2.i2.68","article-title":"Hyperthermic intraperitoneal chemotherapy: rationale and technique","volume":"2","author":"Gonz\u00e1lez-Moreno","year":"2010","journal-title":"World J Gastrointest Oncol"},{"key":"R9-20250826","first-page":"4081","article-title":"lntraperitoneal hyperthermic treatment of implanted peritoneal cancer in rats","volume":"40","author":"Shiu","year":"1980","journal-title":"Cancer Res"},{"issue":"6 Pt 2","key":"R10-20250826","first-page":"2264","article-title":"Potential for therapy of drugs and hyperthermia","volume":"39","author":"Hahn","year":"1979","journal-title":"Cancer Res"},{"issue":"10 Suppl","key":"R11-20250826","first-page":"4853s","article-title":"An update on the anticancer effects of a combination of chemotherapy and hyperthermia","volume":"44","author":"Bull","year":"1984","journal-title":"Cancer Res"},{"key":"R12-20250826","first-page":"1165","article-title":"In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum(II) and mitomycin C","volume":"40","author":"Barlogie","year":"1980","journal-title":"Cancer Res"},{"key":"R13-20250826","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","article-title":"Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer","volume":"21","author":"Verwaal","year":"2003","journal-title":"J Clin Oncol"},{"key":"R14-20250826","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/annonc\/mdl060","article-title":"Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference","volume":"17","author":"Hassan","year":"2006","journal-title":"Ann Oncol"},{"key":"R15-20250826","doi-asserted-by":"crossref","first-page":"7109","DOI":"10.1245\/s10434-021-10048-4","article-title":"Cytoreductive surgery plus HIPEC with and without NIPEC for malignant peritoneal mesothelioma. A propensity-matched analysis","volume":"28","author":"Sugarbaker","year":"2021","journal-title":"Ann Surg Oncol"},{"key":"R17-20250826","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-1-4613-1245-1_17","article-title":"Peritoneal mesothelioma: treatment approach based on natural history","volume":"81","author":"Averbach","year":"1996","journal-title":"Cancer Treat Res"},{"key":"R18-20250826","first-page":"1916","article-title":"Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans","volume":"41","author":"Speyer","year":"1981","journal-title":"Cancer Res"},{"key":"R19-20250826","first-page":"858","article-title":"Technical considerations in the use of intra peritoneal chemotherapy administered by Tenckhoff catheter","volume":"154","author":"Jenkins","year":"1982","journal-title":"Surg Gynecol Obstet"},{"key":"R20-20250826","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"lntraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage Ill ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"key":"R21-20250826","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intra peritoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"key":"R22-20250826","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ejca.2015.09.017","article-title":"Cytoreductive surgery and intra peritoneal chemotherapy versus systemic chemotherapy for co lo rectal peritoneal metastases: a randomised trial","volume":"53","author":"Cashin","year":"2016","journal-title":"Eur J Cancer"},{"key":"R23-20250826","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/ejso.2000.0983","article-title":"Multitargeted antifolate (MTA): Pharmacokinetics of intraperitoneal administration in a rat model","volume":"26","author":"Pestieau","year":"2000","journal-title":"Eur J Surg Oncol"},{"key":"R24-20250826","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1155\/2012\/752643","article-title":"Adjuvant bidirectional chemotherapy using an intraperitoneal port","volume":"2012","author":"Sugarbaker","year":"2012","journal-title":"Gastroenterol Res Pract"}],"container-title":["International Journal of Surgery Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SP9.0000000000000010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T18:01:07Z","timestamp":1756231267000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SP9.0000000000000010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,26]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/sp9.0000000000000010","relation":{},"ISSN":["2468-3574"],"issn-type":[{"type":"electronic","value":"2468-3574"}],"subject":[],"published":{"date-parts":[[2023,9,26]]},"assertion":[{"value":"2023-08-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}